Symptom specific effectiveness of tolterodine ER 4 mg in patients with symptoms of overactive bladder (OAB) in a primary care setting. A phase IV, open-label, single-arm, non-randomized, trial in adult patients with OAB

Trial Profile

Symptom specific effectiveness of tolterodine ER 4 mg in patients with symptoms of overactive bladder (OAB) in a primary care setting. A phase IV, open-label, single-arm, non-randomized, trial in adult patients with OAB

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Apr 2008

At a glance

  • Drugs Tolterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top